ArticleThe Journal of infectious diseases2018
In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus.
Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Drug-induced phospholipidosis as an artifact in antiviral drug repurposing.bioRxiv : the preprint server for biology · 2025Article
- Conserved Filovirus Proteins as Targets of Broad-Spectrum Antivirals.bioRxiv : the preprint server for biology · 2025Article
- Recent advances in the treatment of Ebola disease: A brief overview.PLoS pathogens · 2024Review
- Therapeutic Strategies against Ebola Virus Infection.Viruses · 2022Review
- Drug repositioning: A bibliometric analysis.Frontiers in pharmacology · 2022Review
- Defending Antiviral Cationic Amphiphilic Drugs That May Cause Drug-Induced Phospholipidosis.Journal of chemical information and modeling · 2021Article
- Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2Journal of virology · 2020Article
- Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus disease.Antiviral research · 2020Article
- Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig.Antiviral research · 2020Article
- Safety and Efficacy of Amiodarone in a Patient With COVID-19.JACC. Case reports · 2020Article
- Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention.Advanced therapeutics · 2020Article
- Repurposing approved drugs on the pathway to novel therapies.Medicinal research reviews · 2020Review
- Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?Frontiers in pharmacology · 2020Review
- Review
- Antiviral effect of amiodarone and its possible role in COVID-19: An appraisal.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
At the onset of the 2013-2016 epidemic of Ebola virus disease (EVD), no vaccine or antiviral medication was approved for treatment. Therefore, considerable efforts were directed towards the concept of drug repurposing or repositioning. Amiodarone, an approved multi-ion channel blocker for the treatment of cardiac arrhythmia, was reported to inhibit filovirus entry in vitro. Compassionate use of amiodarone in EVD patients indicated a possible survival benefit. In support of further clinical testing, we confirmed anti-Ebola virus activity of amiodarone in different cell types. Despite promising in vitro results, amiodarone failed to protect guinea pigs from a lethal dose of Ebola virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.